HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ronald E DeGryse Selected Research

preempt

12/2020The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.
12/2020Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis.
7/2019Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.
8/2016OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
9/2015Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
2/2015Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
8/2013OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
10/2011OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
6/2010OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ronald E DeGryse Research Topics

Disease

11Migraine Disorders (Migraine)
12/2020 - 06/2010
9Headache (Headaches)
12/2020 - 06/2010
1Secondary Headache Disorders
08/2013
1Pain (Aches)
06/2010

Drug/Important Bio-Agent (IBA)

10Type A Botulinum Toxins (Botox)FDA Link
12/2020 - 06/2010
9preemptIBA
12/2020 - 06/2010
1Topiramate (Topamax)FDA LinkGeneric
02/2015
1NeuropeptidesIBA
11/2014
1Ion Channels (Ion Channel)IBA
11/2014
1Peptides (Polypeptides)IBA
11/2014
1Tryptamines (Triptans)IBA
08/2013

Therapy/Procedure

5Therapeutics
07/2019 - 06/2010
1Aftercare (After-Treatment)
07/2019